Skip to content

Author

Ellie Johnson

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Case report Open access Jul 2026

Case Report: When access is limited: using CYP3A4 inhibition to maintain clinical benefit from elexacaftor/tezacaftor/ivacaftor

The potential for CYP3A4 inhibition to aid with personalised ETI dosing strategies is supported, particularly in low and middle-income countries where CFTRm access remains limited.

Keirran Hiscock, Michelle Wood, Ellie Johnson et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.